carboplatin + paclitaxel + doxorubicin + cyclophosphamide

This chemotherapy regimen is a multi-drug neoadjuvant treatment protocol used in clinical trials sponsored by Shengjing Hospital for patients with stage II-III triple-negative breast cancer (TNBC). The regimen is typically administered in two sequential phases: an initial 12-week phase of carboplatin (a platinum-based DNA cross-linker) and paclitaxel (a taxane microtubule stabilizer), followed by a second 12-week phase of doxorubicin or epirubicin (anthracycline topoisomerase II inhibitors) combined with cyclophosphamide (an alkylating agent). This combination is designed to maximize pathologic complete response (pCR) prior to surgery by targeting cancer cell replication and division through multiple distinct cytotoxic mechanisms.

Other names

chemotherapy-Shengjing Hospital-triple-negative breast cancerTP-AC regimenneoadjuvant chemotherapy (Shengjing Hospital protocol)carboplatin + paclitaxel + epirubicin + cyclophosphamide